Keywordsalphavirus; live imaging; virus assembly; filopodia; virus egress; Novirhabdovirus; defective particles; fluorescent proteins; pseudorabies virus; firefly luciferase; CRISPR/Cas9; chloroquine; Cyclosporine A; human papillomavirus; HPV; vaccine; FluoroSpot; multiplex immunoassay; dengue virus; flavivirus; reporter replicon; replication; antiviral drug; high-throughput screening; replicating-competent virus; reporter; high-throughput screening; molecular virology; recombinant virus; viral vector; gene delivery; HBV; DHBV; vaccinia virus; vaccine; reporter-expressing virus; Marburg virus; Ebola virus; filoviruses; nonsegmented negative-sense RNA viruses; reverse genetics system; minigenome; full-length clones; virus-like particles; virus rescue; biosafety level 4; recombinant influenza A virus; plasmid-based reverse genetics; virus rescue approaches; reporter genes; fluorescence; luminescence; replicating-competent reporter-expressing influenza A virus; Chikungunya virus; reporter virus; antiviral; neutralization antibody; Newcastle disease virus; vaccine vector; human vaccines; veterinary vaccines; Amphibians; Xenopus; iridovirus; DNA viruses; reporter virus, recombinant virus; arenavirus; hemorrhagic fever; reporter genes; reverse genetic techniques; vaccines; antivirals; fluorescent reporter virus; bioluminescent reporter virus; paramyxovirus; orthomyxovirus
